The Scheduling of MDMA: A Pharmacist's Perspective
Journal of Psychoactive Drugs July 1, 1985 DOI: 10.1080/02791072.1985.10472337 via OpenAlex
Summary
AI-generated from the abstractA pharmacist argues against the emergency scheduling of MDMA (Ecstasy) as a Schedule I controlled substance, contending that the drug has legitimate therapeutic potential in psychotherapy and that its risks are not sufficiently understood to justify the most restrictive classification. The author reviews the pharmacology, clinical uses, and potential adverse effects of MDMA, and criticizes the scheduling process for lacking thorough scientific evaluation. The piece calls for more research and a more balanced regulatory approach that considers both the benefits and risks of the substance.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Citations | 26 |
| Key finding | The author argues that MDMA should not have been placed in Schedule I because its therapeutic potential and risks were not adequately assessed. |
Abstract
(1985). The Scheduling of MDMA: A Pharmacist's Perspective. Journal of Psychoactive Drugs: Vol. 17, No. 3, pp. 167-171.